Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper
Authors:
- Sarah BaillySBSarah Bailly
- Guillaume CartronGCGuillaume Cartron
- Raul CórdobaRCRaul Córdoba
- Paolo CorradiniPCPaolo Corradini
- Isacco FerrariniIFIsacco Ferrarini
- Wendy OsborneWOWendy Osborne
- Andreas RosenwaldARAndreas Rosenwald
- Juan‐Manuel SanchoJSJuan‐Manuel Sancho
- Hervé TillyHTHervé Tilly
- Eric Van Den NesteENEric Van Den Neste
Open Access
- 7 June 2022
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 505-517
Abstract
The ubiquitous, early‐stage expression, efficient internalization, limited off‐target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti‐CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti‐CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B‐cell lymphoma and consider approaches to the use of anti‐CD19 therapy.Keywords
This publication has 97 references indexed in Scilit:
- Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyondLeukemia & Lymphoma, 2013
- Targeting CD19 in B-cell lymphoma: emerging role of SAR3419Cancer Management and Research, 2013
- CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology & Oncology, 2012
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibodyBlood, 2010
- PotentIn vitroandIn vivoActivity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and LeukemiaCancer Research, 2008
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- The CD19–CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and AutoimmunityImmunity, 1997
- Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.Journal of Experimental Medicine, 1993